Medical Microinstruments (MMI) raised $125 million in a Series D financing to expand its Symani Surgical System and pursue new microsurgery applications, including an experimental approach for Alzheimer’s. The funding is intended to widen the reach of Symani, a robotic platform designed for precision microsurgical procedures, while extending development into additional use cases. The report also highlights Alzheimer’s as one area of exploration for the microsurgery technology, reflecting continued interest in leveraging minimally disruptive or highly targeted procedural approaches for CNS-related indications. For investors and clinicians, the combination of commercial scaling and new clinical exploration is a notable dual track for a medtech-adjacent healthcare technology company.